Tarsus appoints Elizabeth Yeu, M.D. to Board of Directors

Tarsus Pharmaceuticals, Inc.

Dr. Yeu appointed as Class II director effective Dec 31, 2021; term expires at 2022 annual meeting.
She continues as Chief Medical Advisor under consulting agreement with $240k annual cash compensation.
Dr. Yeu brings over 20 years of eye care experience; will serve on Science and Technology Committee.
Appointment comes as Tarsus nears potential commercialization of lead candidate TP-03 for Demodex blepharitis.
No arrangements or understandings for her election; standard indemnification agreement.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Elizabeth Yeu-Lin, M.D.

Director

TARS · Tarsus Pharmaceuticals, Inc.

Effective: 2021-12-31
Filed: January 4, 2022, 6:59 PM ET

appointed Elizabeth Yeu-Lin, M.D. to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Elizabeth Yeu-Lin, M.D. was appointed as Director at Tarsus Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Elizabeth Yeu-Lin, M.D. to the Board, effective immediately.

View on SEC.gov

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-22-000002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.